AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8773063
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid 6.5 mg/kg
Trial: 8773063
Drug: Ibuprofen 7
RxNorm normalized name: hydrocodone-ibuprofen 7.5 mg-200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 7 mg/kg
Trial: 1689173
Drug: Terazosin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (10 mg/day)
Trial: 26549134
Drug: Bilateral infraorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral infraorbital and infratrochlear nerve blocks with 10 mL of 0.25% levobupivacaine (Group LB)
Trial: 21775113
Drug: Prescription omega-3-acid
RxNorm normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription omega-3-acid ethyl esters (POM3)
Trial: 18040542
Drug: Clinical holistic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical holistic medicine (CHM)
Trial: 18040542
Drug: Standard psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychiatric treatment (TAU)
Trial: 11897585
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of artemisinin daily for 5 days (group A; n = 40)
Trial: 11897585
Drug: Artemisinin at
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin at a dose of 100 mg per day for 2 days, increased to 250 mg per day for 2 consecutive days, and 500 mg on the fifth day (group B; n = 37)
Trial: 11897585
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (500 mg daily for 5 days)
Trial: 11897585
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (escalating doses of artemisinin)
Trial: 10631689
Drug: High-dose (dose-intensive)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (dose-intensive) therapy for breast cancer
Trial: 1702552
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of Heparin (Kakkar protocol)
Trial: 31534374
Drug: Polyphenol compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol compound supplementation (Vertigoval) for 60 days
Trial: 28675566
Drug: Glutamine-fiber-oligosaccharide treatment
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-fiber-oligosaccharide treatment group (n=11)
Trial: 28675566
Drug: Glutamine F
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine F treatment group (n=11)
Trial: 25851721
Drug: Comprehensive medical
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive medical education program (1h/day for 5 days) and specific drug therapy
Trial: 25851721
Drug: Only drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only drug therapy
Trial: 23453362
Drug: Initial serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial serum magnesium concentration >1.6 mg/dL
Trial: 21084184
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (CT) with cisplatin (80 mg/m(2)) and infusional 5 fluorouracil (1000 mg/m(2)/d) on days 1 and 21
Trial: 21084184
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation therapy (CRT) with cisplatin (80 mg/m(2)), infusional 5 fluorouracil (800 mg/m(2)/d) starting on day 21, and radiation therapy (35 Gy in 15 fractions over 3 weeks)
Trial: 19833052
Drug: Prednisolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (50 mg per day)
Trial: 19833052
Drug: Aciclovir (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aciclovir (2000 mg per day)
Trial: 15371775
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of 0.25% bupivacaine
Trial: 15371775
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose caudal injection of 0.25% bupivacaine
Trial: 7732541
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride tablets administered since age 2
Trial: 3133708
Drug: Trazodone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (150 mg daily)
Trial: 3133708
Drug: Mianserin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (30 mg for 7 days, then 60 mg daily)
Trial: 3133708
Drug: Dothiepin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (75 mg for 1 week, then 150 mg daily)
Trial: 3133708
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 mg for 1 week, then 100 mg daily)
Trial: 29903422
Drug: Daily bladder
RxNorm normalized name: Pumpkin Seed Extract/Soy Germ 300 MG Oral Capsule [DAILY BLADDER COMFORT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bladder irrigation with 450 cc sterile normal saline, in 3 150‐mL doses, for 3 consecutive days
Trial: 29903422
Drug: Daily bladder
RxNorm normalized name: Pumpkin Seed Extract/Soy Germ 300 MG Oral Capsule [DAILY BLADDER COMFORT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bladder irrigation with normal saline
Trial: 21790238
Drug: Ubenimex capsule
RxNorm normalized name: Ubenimex
DrugBank: Ubenimex (DB03424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubenimex capsule (30mg daily for 8 weeks)
Trial: 14742994
Drug: Daclizumab treatment
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab treatment in combination with tacrolimus and mycophenolate mofetil
Trial: 14742994
Drug: Calculated fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated fractional excretion of sIL‐2Rα
Trial: 11393352
Drug: Conventional cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cyclic chemotherapy with rHuG-CSF
Trial: 11393352
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy with rHuG-CSF
Trial: 9003265
Drug: Low-dose unfractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unfractionated heparin
Trial: 7939756
Drug: Paclitaxel (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (150 mg/m2) followed by Doxorubicin (50 mg/m2)
Trial: 7939756
Drug: Paclitaxel (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (200 mg/m2) and Doxorubicin (75 mg/m2) alternating every 3 weeks
Trial: 3070520
Drug: DZ 15
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DZ 15 mg
Trial: 3070520
Drug: DZ-CR 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZ-CR 20 mg
Trial: 26668177
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Trial: 23278670
Drug: Mg titanate
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mg titanate
Trial: 23278670
Drug: blasted Mg
RxNorm normalized name: Arctic Blast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blasted Mg titanate
Trial: 23683558
Drug: Intraoperative dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative dobutamine infusion (3 μg/kg per minute or 5 μg/kg per minute)
Trial: 20528283
Drug: Classical Sequential
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical Sequential Advertising (CSA)
Trial: 8533005
Drug: Felodipine (Plendil)
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine (Plendil) 5 mg/day
Trial: 8533005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of felodipine with other antihypertensive drugs (ACE inhibitors, beta blockers, diuretics)
Trial: 8533005
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of aspirin (75 mg/day)
Trial: 339282
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg 15‐methyl‐PGF2alpha‐methyl ester in a rapid releasing base, administered 6 hours prior to operation
Trial: 339282
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg 15‐methyl‐PGF2alpha‐methyl ester in a slow releasing base, administered 12 hours prior to operation
Trial: 19948506
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg if needed)
Trial: 11583479
Drug: Etoricoxib 5
RxNorm normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 5 mg
Trial: 11583479
Drug: Etoricoxib 10
RxNorm normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 10 mg
Trial: 11583479
Drug: Etoricoxib 20
RxNorm normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 20 mg
Trial: 11583479
Drug: Etoricoxib 40
RxNorm normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 40 mg
Trial: 11583479
Drug: Etoricoxib (5-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (5-120 mg range)
Trial: 9836104
Drug: IgA anti‐transglutaminase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgA anti‐transglutaminase antibodies by enzyme‐linked immunosorbent assay test
Trial: 8015820
Drug: BV (Immunomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BV (Immunomodulation therapy)
Trial: 26474041
Drug: Acetaminophen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (500 mg twice daily)
Trial: 24471868
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg alone (Group A)
Trial: 24471868
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg plus Propiverine 10 mg (Group B)
Trial: 24471868
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg plus Propiverine 20 mg (Group C)
Trial: 19455984
Drug: Intravenous infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of 400 ml of ozonized sodium chloride solution (pO3) containing 1.6 microg/ml of O3 twice weekly for 21 days
Trial: 19455984
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibacterial therapy only)
Trial: 19455984
Drug: Blood ozonization
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood ozonization in combination with antibiotics
Trial: 15938923
Drug: CPT‐11 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 90 ‐ 25 mg/m(2) continuous infusion for 10 h and folinic acid (FA) 30 mg x m(‐2) x d(‐1) + 5‐FU 425 mg x m(‐2) x d(‐1) x 2 d continuous infusion for 48 h, every two weeks for a total of no less than six cycles (Group A)
Trial: 15938923
Drug: CPT‐11 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 90 ‐ 125 mg/m(2) continuous infusion for 10 h every two weeks for a total of no less than six cycles and capecitabine 1250 mg x m(‐2) x d(‐1) by oral divided into two doses, continuously taken without interruption for three months (Group B)
Trial: 9137123
Drug: Clomipramine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (200 mg i.v.)
Trial: 31436231
Drug: Ultrasound-guided percutaneous
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided percutaneous RFA plus intravenous infusion of LTLD (combination group, n = 11)
Trial: 23082846
Drug: ProDisc-L total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProDisc-L total disc replacement (TDR)
Trial: 19943947
Drug: Nicotine 4
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 4 mg gum or nicotine 10 mg inhaler
Trial: 15250817
Drug: Empirically Supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirically Supported Therapies (ESTs)
Trial: 11675905
Drug: Co-amoxiclav (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (625 mg tablets three times daily for 7 days)
Trial: 9041571
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 mg.kg‐1)/propofol bolus (0.5 mg.kg‐1 every 3 min)
Trial: 7705855
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon alpha-2a plus podophyllin 25% W/V administered twice per week, preceded by IFN alpha-2a three times weekly for one week
Trial: 7705855
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus podophyllin 25% W/V administered in the same schedule
Trial: 3311619
Drug: Estrostep (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrostep (new graduated estrogen formulation)
Trial: 3311619
Drug: Loestrin 1/20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loestrin 1/20, Loestrin 1.5/30, Norlestrin 1/50 (constant-dosed oral contraceptives)
Trial: 3311619
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four combination oral contraceptives
Trial: 15927989
Drug: Rho-kinase inhibitor
RxNorm normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rho-kinase inhibitor fasudil
Trial: 10407221
Drug: Anabolic-androgenic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks
Trial: 10407221
Drug: Triptorelin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin administration for 5 weeks
Trial: 2147527
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day toremifene
Trial: 2147527
Drug: 240 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg/day toremifene
Trial: 2147527
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day tamoxifen
Trial: 6998794
Drug: Trithiozine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trithiozine (1200 mg/day)
Trial: 30983457
Drug: Topical ethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ethyl chloride anesthetic spray
Trial: 30983457
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine subdermal injection
Trial: 31823822
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with methotrexate (MTX) and zoledronic acid (ZOL)
Trial: 31823822
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) monotherapy
Trial: 20193338
Drug: Thalidomide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (50 mg p.o. bid) administered on days 1 to 5 after the start of chemotherapy
Trial: 20193338
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ramosetron 0.3 mg i.v. and metoclopramide 20 mg i.m. 30 min prior to chemotherapy)
Trial: 15083445
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=12)
Trial: 11535548
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day raloxifene
Trial: 9500490
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg administered 2 hours before oral contraceptive on pill day 6
Trial: 20456248
Drug: 50 U/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 U/ml NT 201 dilution
Trial: 20456248
Drug: 20 U/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 U/ml NT 201 dilution
Trial: 10227008
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐oestradiol + 2.5, 5, 10 or 15 mg dydrogesterone (orally once a day)
Trial: 8916980
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist plus add-back hormone replacement therapy (HRT)
Trial: 8916980
Drug: 25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 micrograms oestradiol patches plus continuous medroxyprogesterone acetate (5 mg)
Trial: 8916980
Drug: Full bone-sparing
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full bone-sparing dose of oral oestradiol (2 mg daily)
Trial: 30408383
Drug: Depot Medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot Medroxyprogesterone Acetate combined with Gonadotropin-Releasing Hormone (GnRH) analog
Trial: 22506940
Drug: Patient-Controlled Analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Analgesia (PCA) with 1 mg IV morphine on-demand doses
Trial: 22506940
Drug: Patient-Controlled Analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Analgesia (PCA) with 1.5 mg IV morphine on-demand doses
Trial: 22506940
Drug: Non-PCA treatment
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PCA treatment (initial dose of 0.1 mg/kg IV morphine followed by physician-managed analgesia)
Trial: 8675589
Drug: Parenteral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral estrogen (im polyestradiol phosphate, 240 mg twice monthly)
Trial: 8675589
Drug: Parenteral testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral testosterone (im injections, 250 mg/week)
Trial: 6359109
Drug: Labetalol (non‐cardioselective,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (non‐cardioselective, alpha‐blocker)
Trial: 28490560
Drug: Team-care deprescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Team-care deprescribing practice using a deprescribing guide (Beers and STOPP criteria, drug interaction checking)
Trial: 23034965
Drug: Long-chain n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain n-3 PUFAs (3.36 g/d)
Trial: 17963164
Drug: Continue GC
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue GC treatment
Trial: 17963164
Drug: Withdraw GC
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdraw GC treatment
Trial: 15167190
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients managed by internal medicine residents before the addition of a second physician)
Trial: 1809445
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg each night for 4 weeks
Trial: 6308754
Drug: Mecillinam (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecillinam (200 mg daily for 25 days)
Trial: 23748920
Drug: apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apixaban 2.5 mg BID
Trial: 23748920
Drug: apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apixaban 5 mg BID
Trial: 17939152
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (huperzine A 0.2 mg)
Trial: 17939152
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (huperzine A 0.2 mg)
Trial: 29394348
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg/day for 4 weeks
Trial: 26725583
Drug: Nefopam 20
RxNorm normalized name: nefopam 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 20 mg intravenous (i.v.) 30 min before surgery, followed by an i.v. infusion (5 mg/h) for 24 h